Skip to main content
SpringerLink
Log in

The endocannabinoid system as a target for modelling psychosis

  • Review
  • Published:
Psychopharmacology Aims and scope Submit manuscript

Abstract

Introduction

Model psychosis is characterised by experimentally induced symptoms of withdrawal from reality, frequently accompanied by perceptual disturbances, thought disorders, delusional ideas and sometimes by hallucinations. These “altered states of consciousness” provide a long-standing and valid approach to enhance our understanding of certain aspects of schizophrenia.

Discussion

Targeting the endocannabinoid system to investigate its involvement in the pathophysiology of schizophrenia became increasingly relevant with the discovery of this system and amounting epidemiological evidence for a deleterious influence of cannabis use on both manifestation and course of the disease. The majority of studies in the field are targeted to investigate drug effect of cannabis and cannabinoids not immediately related to psychosis.

Conclusion

In this review, we summarise studies relevant for or designed as model psychosis experiments. Based on the data available, we examine the contribution of these studies to an improved neurobiological assessment of endocannabinoid functioning in psychosis and schizophrenia. An outline for future studies in the field and cross-links to other approaches to model psychosis is provided.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Ames F (1958) A clinical and metabolic study of acute intoxication with cannabis sative and its role in the model psychoses. J Ment Sci 104:972–999

    PubMed  CAS  Google Scholar 

  • Arseneault L, Cannon M, Witton J, Murray RM (2004) Causal association between cannabis and psychosis: examination of the evidence. Br J Psychiatry 184:110–117

    Article  PubMed  Google Scholar 

  • Ashton C (2001) Pharmacology and effects of cannabis: a brief review. Br J Psychiatry 178:101–106

    Article  PubMed  CAS  Google Scholar 

  • Beringer K, von Baeyer W, Marx H (1932) Zur Klinik des Haschischrausches. Nervenarzt 5:337–350

    Google Scholar 

  • Bisogno T, Hanus L, De Petrocellis L, Tchilibon S, Ponde DE, Brandi I, Moriello AS, Davis JB, Mechoulam R, Di Marzo V (2001) Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol 134:845–852

    Article  PubMed  CAS  Google Scholar 

  • Borgwardt SJ, Allen P, Bhattacharyya S, Fusar-Poli P, Crippa JA, Seal ML, Fraccaro V, Atakan Z, Martin-Santos R, O'Carroll C, Rubia K, McGuire PK (2008) Neural basis of delta-9-tetrahydrocannabinol and cannabidiol: effects during response inhibition. Biol Psychiatry 64:966–673

    Article  PubMed  CAS  Google Scholar 

  • Bossong MG, van Berckel BN, Boellaard R, Zuurman L, Schuit RC, Windhorst AD, van Gerven JM, Ramsey NF, Lammertsma AA, Kahn RS (2009) Delta 9-tetrahydrocannabinol induces dopamine release in the human striatum. Neuropsychopharmacology 34:759–766

    Article  PubMed  CAS  Google Scholar 

  • Burns HD, Van Laere K, Sanabria-Bohorquez S, Hamill TG, Bormans G, Eng WS, Gibson R, Ryan C, Connolly B, Patel S, Krause S, Vanko A, Van Hecken A, Dupont P, De Lepeleire I, Rothenberg P, Stoch SA, Cote J, Hagmann WK, Jewell JP, Lin LS, Liu P, Goulet MT, Gottesdiener K, Wagner JA, de Hoon J, Mortelmans L, Fong TM, Hargreaves RJ (2007) [18F]MK-9470, a positron emission tomography (PET) tracer for in vivo human PET brain imaging of the cannabinoid-1 receptor. Proc Natl Acad Sci U S A 104:9800–9805

    Article  PubMed  CAS  Google Scholar 

  • Chait LD, Perry JL (1994) Acute and residual effects of alcohol and marijuana, alone and in combination, on mood and performance. Psychopharmacology (Berl) 115:340–349

    Article  CAS  Google Scholar 

  • Chang L, Chronicle EP (2007) Functional imaging studies in cannabis users. Neuroscientist 13:422–432

    Article  PubMed  Google Scholar 

  • Clapper JR, Mangieri RA, Piomelli D (2009) The endocannabinoid system as a target for the treatment of cannabis dependence. Neuropharmacology 56(Suppl 1):235–243

    Article  PubMed  CAS  Google Scholar 

  • Crippa JA, Zuardi AW, Garrido GE, Wichert-Ana L, Guarnieri R, Ferrari L, Azevedo-Marques PM, Hallak JE, McGuire PK, Filho Busatto G (2004) Effects of cannabidiol (CBD) on regional cerebral blood flow. Neuropsychopharmacology 29:417–426

    Article  PubMed  CAS  Google Scholar 

  • Curran HV, Brignell C, Fletcher S, Middleton P, Henry J (2002) Cognitive and subjective dose-response effects of acute oral delta(9)-tetrahydrocannabinol (THC) in infrequent cannabis users. Psychopharmacology (Berl) 164:61–70

    Article  CAS  Google Scholar 

  • Dalton WS, Martz R, Lemberger L, Rodda BE, Forney RB (1976) Influence of cannabidiol on delta-9-tetrahydrocannabinol effects. Clin Pharmacol Ther 19:300–309

    PubMed  CAS  Google Scholar 

  • Dean B, Sundram S, Bradbury R, Scarr E, Copolov D (2001) Studies on [3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use. Neuroscience 103:9–15

    Article  PubMed  CAS  Google Scholar 

  • Devane WA, Dysarz FA III, Johnson MR, Melvin LS, Howlett AC (1988) Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 34:605–613

    PubMed  CAS  Google Scholar 

  • Di Marzo V (2008) Targeting the endocannabinoid system: to enhance or reduce? Nat Rev Drug Discov 7:438–455

    Article  PubMed  CAS  Google Scholar 

  • D'Souza CD, Perry E, MacDougall L, Ammerman Y, Cooper T, Wu Y-T, Braley G, Gueorguieva R, Krystal JH (2004) The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology 29:1558–1572

    Article  PubMed  CAS  Google Scholar 

  • D'Souza DC, Abi-Saab WM, Madonick S, Forselius-Bielen K, Doersch A, Braley G, Gueorguieva R, Cooper TB, Krystal JH (2005) Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biol Psychiatry 57:594–608

    Article  PubMed  CAS  Google Scholar 

  • D'Souza DC, Braley G, Blaise R, Vendetti M, Oliver S, Pittman B, Ranganathan M, Bhakta S, Zimolo Z, Cooper T, Perry E (2008a) Effects of haloperidol on the behavioral, subjective, cognitive, motor, and neuroendocrine effects of delta-9-tetrahydrocannabinol in humans. Psychopharmacology (Berl) 198:587–603

    Article  CAS  Google Scholar 

  • D'Souza DC, Ranganathan M, Braley G, Gueorguieva R, Zimolo Z, Cooper T, Perry E, Krystal J (2008b) Blunted psychotomimetic and amnestic effects of delta-9-tetrahydrocannabinol in frequent users of cannabis. Neuropsychopharmacology 33:2505–2516

    Article  PubMed  CAS  Google Scholar 

  • Eggan SM, Hashimoto T, Lewis DA (2008) Reduced cortical cannabinoid 1 receptor messenger RNA and protein expression in schizophrenia. Arch Gen Psychiatry 65:772–784

    Article  PubMed  Google Scholar 

  • Elsohly MA, Slade D (2005) Chemical constituents of marijuana: the complex mixture of natural cannabinoids. Life Sci 78:539–548

    Article  PubMed  CAS  Google Scholar 

  • Fusar-Poli P, Crippa JA, Bhattacharyya S, Borgwardt SJ, Allen P, Martin-Santos R, Seal M, Surguladze SA, O’Carrol C, Atakan Z, Zuardi AW, McGuire PK (2009) Distinct effects of {delta}9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. Arch Gen Psychiatry 66:95–105

    Article  PubMed  CAS  Google Scholar 

  • Gaoni Y, Mechoulam R (1964) Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Soc 86:1646–1647

    Article  CAS  Google Scholar 

  • Giuffrida A, Parsons LH, Kerr TM, de Fonseca FR, Navarro M, Piomelli D (1999) Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nat Neurosci 2:358–363

    Article  PubMed  CAS  Google Scholar 

  • Giuffrida A, Leweke FM, Gerth CW, Schreiber D, Koethe D, Faulhaber J, Klosterkotter J, Piomelli D (2004) Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology 29:2108–2114

    Article  PubMed  CAS  Google Scholar 

  • Glass M, Dragunow M, Faull RL (1997) Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience 77:299–318

    Article  PubMed  CAS  Google Scholar 

  • Häfner H, an der Heiden W (1999) The course of schizophrenia in the light of modern follow-up studies: the ABC and WHO studies. Eur Arch Psychiatry Clin Neurosci 249(Suppl 4):14–26

    PubMed  Google Scholar 

  • Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR, Rice KC (1990) Cannabinoid receptor localization in brain. Proc Natl Acad Sci USA 87:1932–1936

    Article  PubMed  CAS  Google Scholar 

  • Hollister LE (1973) Cannabidiol and cannabinol in man. Experientia 29:825–826

    Article  PubMed  CAS  Google Scholar 

  • Hollister LE, Gillespie H (1975) Interactions in man of delta-9-tetrahydrocannabinol. II. Cannabinol and cannabidiol. Clin Pharmacol Ther 18:80–83

    PubMed  CAS  Google Scholar 

  • Isbell H, Gorodetzsky CW, Jasinski D, Claussen U, von Spulak F, Korte F (1967) Effects of (−)delta-9-trans-tetrahydrocannabinol in man. Psychopharmacologia 11:184–188

    Article  PubMed  CAS  Google Scholar 

  • Johns A (2001) Psychiatric effects of cannabis. Br J Psychiatry 178:116–122

    Article  PubMed  CAS  Google Scholar 

  • Kano M, Ohno-Shosaku T, Hashimotodani Y, Uchigashima M, Watanabe M (2009) Endocannabinoid-mediated control of synaptic transmission. Physiol Rev 89:309–380

    Article  PubMed  CAS  Google Scholar 

  • Karniol IG, Shirakawa I, Kasinski N, Pfeferman A, Carlini EA (1974a) Cannabidiol interferes with the effects of Δ9-tetrahydrocannabinol in man. Eur J Pharmacol 28:172–177

    Article  PubMed  CAS  Google Scholar 

  • Karniol IG, Takahashi RN, Musty RE (1974b) Effects of delta9-tetrahydrocannabinol and cannabinol on operant performance in rats. Arch Int Pharmacodyn Ther 212:230–237

    PubMed  CAS  Google Scholar 

  • Kirk JM, de Wit H (1999) Responses to oral delta9-tetrahydrocannabinol in frequent and infrequent marijuana users. Pharmacol Biochem Behav 63:137–142

    Article  PubMed  CAS  Google Scholar 

  • Kirk JM, Doty P, De Wit H (1998) Effects of expectancies on subjective responses to oral delta9-tetrahydrocannabinol. Pharmacol Biochem Behav 59:287–293

    Article  PubMed  CAS  Google Scholar 

  • Koethe D, Gerth CW, Neatby MA, Haensel A, Thies M, Schneider U, Emrich HM, Klosterkotter J, Schultze-Lutter F, Leweke FM (2006) Disturbances of visual information processing in early states of psychosis and experimental delta-9-tetrahydrocannabinol altered states of consciousness. Schizophr Res 88:142–150

    Article  PubMed  Google Scholar 

  • Koethe D, Llenos IC, Dulay JR, Hoyer C, Torrey EF, Leweke FM, Weis S (2007) Expression of CB1 cannabinoid receptor in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression. J Neural Transm 114:1055–1063

    Article  PubMed  CAS  Google Scholar 

  • Koethe D, Giuffrida A, Schreiber D, Hellmich M, Schultze-Lutter F, Ruhrmann S, Klosterkotter J, Piomelli D, Leweke FM (2009a) Anandamide elevation in CSF of prodromal states of schizophrenia. Br J Psychiatry 194:371–372

    Article  PubMed  Google Scholar 

  • Koethe D, Kranaster L, Hoyer C, Gross S, Neatby MA, Schultze-Lutter F, Ruhrmann S, Klosterkotter J, Hellmich M, Leweke FM (2009b) Binocular depth inversion as a paradigm of reduced visual information processing in prodromal state, antipsychotic-naive and treated schizophrenia. Eur Arch Psychiatry Clin Neurosci 259:195–202

    Article  PubMed  Google Scholar 

  • Leweke FM, Koethe D (2008) Cannabis and psychiatric disorders: it is not only addiction. Addict Biol 13:264–275

    Article  PubMed  Google Scholar 

  • Leweke FM, Giuffrida A, Wurster U, Emrich HM, Piomelli D (1999a) Elevated endogenous cannabinoids in schizophrenia. NeuroReport 10:1665–1669

    Article  PubMed  CAS  Google Scholar 

  • Leweke FM, Schneider U, Thies M, Münte TF, Emrich HM (1999b) Effects of synthetic Δ9-tetrahydrocannabinol on binocular depth inversion of natural and artificial objects in man. Psychopharmacology 142:230–235

    Article  PubMed  CAS  Google Scholar 

  • Leweke FM, Schneider U, Radwan M, Schmidt E, Emrich HM (2000) Different effects of nabilone and cannabidiol on binocular depth inversion in man. Pharmacol Biochem Behav 66:175–181

    Article  PubMed  CAS  Google Scholar 

  • Leweke FM, Giuffrida A, Koethe D, Schreiber D, Nolden BM, Kranaster L, Neatby MA, Schneider M, Gerth CW, Hellmich M, Klosterkotter J, Piomelli D (2007) Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: impact of cannabis use. Schizophr Res 94:29–36

    Article  PubMed  Google Scholar 

  • Maldonado R, Valverde O, Berrendero F (2006) Involvement of the endocannabinoid system in drug addiction. Trends Neurosci 29:225–232

    Article  PubMed  CAS  Google Scholar 

  • Mathew RJ, Wilson WH, Tant SR (1989) Acute changes in cerebral blood flow associated with marijuana smoking. Acta Psychiatr Scand 79:118–128

    Article  PubMed  CAS  Google Scholar 

  • Mathew RJ, Wilson WH, Humphreys DF, Lowe JV, Wiethe KE (1992) Regional cerebral blood flow after marijuana smoking. J Cereb Blood Flow Metab 12:750–758

    PubMed  CAS  Google Scholar 

  • Mathew RJ, Wilson WH, Coleman RE, Turkington TG, DeGrado TR (1997) Marijuana intoxication and brain activation in marijuana smokers. Life Sci 60:2075–2089

    Article  PubMed  CAS  Google Scholar 

  • Mathew RJ, Wilson WH, Chiu NY, Turkington TG, Degrado TR, Coleman RE (1999) Regional cerebral blood flow and depersonalization after tetrahydrocannabinol administration. Acta Psychiatr Scand 100:67–75

    Article  PubMed  CAS  Google Scholar 

  • Mathew RJ, Wilson WH, Turkington TG, Hawk TC, Coleman RE, DeGrado TR, Provenzale J (2002) Time course of tetrahydrocannabinol-induced changes in regional cerebral blood flow measured with positron emission tomography. Psychiatry Research: Neuroimaging 116:173–185

    Article  PubMed  CAS  Google Scholar 

  • Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346:561–564

    Article  PubMed  CAS  Google Scholar 

  • McDonald J, Schleifer L, Richards JB, de Wit H (2003) Effects of THC on behavioral measures of impulsivity in humans. Neuropsychopharmacology 28:1356–1365

    Article  PubMed  CAS  Google Scholar 

  • Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, Jones PB, Burke M, Lewis G (2007) Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 370:319–328

    Article  PubMed  Google Scholar 

  • Moreau de Tours J-J (1845) Du hachisch et de l'aliénation mentale, Études psychologiques. Fortin et Masson, Fortin et Masson

  • Morgan CJ, Curran HV (2008) Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis. Br J Psychiatry 192:306–307

    Article  PubMed  Google Scholar 

  • Munro S, Thomas KL, Abu Shaar M (1993) Molecular characterization of a peripheral receptor for cannabinoids. Nature 365:61–65

    Article  PubMed  CAS  Google Scholar 

  • Ohlsson A, Lindgren JE, Wahlen A, Agurell S, Hollister LE, Gillespie HK (1980) Plasma delta-9 tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking. Clin Pharmacol Ther 28:409–416

    PubMed  CAS  Google Scholar 

  • O'Leary DS, Block RI, Flaum M, Schultz SK, Boles Ponto LL, Watkins GL, Hurtig RR, Andreasen NC, Hichwa RD (2000) Acute marijuana effects on rCBF and cognition: a PET study. NeuroReport 11:3835–3841

    Article  PubMed  Google Scholar 

  • O'Leary DS, Block RI, Koeppel JA, Flaum M, Schultz SK, Andreasen NC, Ponto LB, Watkins GL, Hurtig RR, Hichwa RD (2002) Effects of smoking marijuana on brain perfusion and cognition. Neuropsychopharmacology 26:802–816

    Article  PubMed  Google Scholar 

  • Pacher P, Batkai S, Kunos G (2006) The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 58:389–462

    Article  PubMed  CAS  Google Scholar 

  • Perez-Reyes M, Timmons MC, Lipton MA, Christensen HD, Davis KH, Wall ME (1973) A comparison of the pharmacological activity of delta 9-tetrahydrocannabinol and its monohydroxylated metabolites in man. Experientia 29:1009–1010

    Article  PubMed  CAS  Google Scholar 

  • Piomelli D (2003) The molecular logic of endocannabinoid signalling. Nat Rev, Neurosci 4:873–884

    Article  CAS  Google Scholar 

  • Piomelli D, Giuffrida A, Calignano A, Rodriguez de Fonseca F (2000) The endocannabinoid system as a target for therapeutic drugs. Trends Pharmacol Sci 21:218–224

    Article  PubMed  CAS  Google Scholar 

  • Ranganathan M, D'Souza DC (2006) The acute effects of cannabinoids on memory in humans: a review. Psychopharmacology (Berl) 188:425–444

    Article  CAS  Google Scholar 

  • Schaefer CF, Gunn CG, Dubowski KM (1977) Dose-related heart-rate, perceptual, and decisional changes in man following marihuana smoking. Percept Mot Skills 44:3–16

    PubMed  CAS  Google Scholar 

  • Schreiber D, Harlfinger S, Nolden BM, Gerth CW, Jaehde U, Schomig E, Klosterkotter J, Giuffrida A, Astarita G, Piomelli D, Markus Leweke F (2007) Determination of anandamide and other fatty acyl ethanolamides in human serum by electrospray tandem mass spectrometry. Anal Biochem 361:162–168

    Article  PubMed  CAS  Google Scholar 

  • Solowij N (1998) Cannabis and cognitive functioning. Cambridge University Press, Cambridge

    Google Scholar 

  • Solowij N, Michie PT (2007) Cannabis and cognitive dysfunction: parallels with endophenotypes of schizophrenia? J Psychiatry Neurosci 32:30–52

    PubMed  Google Scholar 

  • Solowij N, Stephens R, Roffman RA, Babor T (2002a) Does marijuana use cause long-term cognitive deficits? JAMA 287:2653–2654 author reply 2654

    Article  PubMed  Google Scholar 

  • Solowij N, Stephens RS, Roffman RA, Babor T, Kadden R, Miller M, Christiansen K, McRee B, Vendetti J (2002b) Cognitive functioning of long-term heavy cannabis users seeking treatment. J Am Med Assoc 287:1123–1131

    Article  Google Scholar 

  • Spencer KM, Nestor PG, Niznikiewicz MA, Salisbury DF, Shenton ME, McCarley RW (2003) Abnormal neural synchrony in schizophrenia. J Neurosci 23:7407–7411

    PubMed  CAS  Google Scholar 

  • Uhlhaas PJ, Haenschel C, Nikolic D, Singer W (2008) The role of oscillations and synchrony in cortical networks and their putative relevance for the pathophysiology of schizophrenia. Schizophr Bull 34:927–943

    Article  PubMed  Google Scholar 

  • Volkow ND, Gillespie H, Mullani N, Tancredi L, Grant C, Ivanovic M, Hollister L (1991) Cerebellar metabolic activation by delta-9-tetrahydro-cannabinol in human brain: a study with positron emission tomography and 18F-2-fluoro-2-deoxyglucose. Psychiatry Res 40:69–78

    Article  PubMed  CAS  Google Scholar 

  • Wachtel SR, ElSohly MA, Ross SA, Ambre J, de Wit H (2002) Comparison of the subjective effects of delta(9)-tetrahydrocannabinol and marijuana in humans. Psychopharmacology 161:331–339

    Article  PubMed  CAS  Google Scholar 

  • Wall ME, Sadler BM, Brine D, Taylor H, Perez-Reyes M (1983) Metabolism, disposition, and kinetics of delta-9-tetrahydrocannabinol in men and women. Clin Pharmacol Ther 34:352–363

    PubMed  CAS  Google Scholar 

  • Weinstein A, Brickner O, Lerman H, Greemland M, Bloch M, Lester H, Chisin R, Mechoulam R, Bar-Hamburger R, Freedman N, Even-Sapir E (2008) Brain imaging study of the acute effects of delta9-tetrahydrocannabinol (THC) on attention and motor coordination in regular users of marijuana. Psychopharmacology (Berl) 196:119–131

    Article  CAS  Google Scholar 

  • Wilson RI, Nicoll RA (2002) Endocannabinoid signaling in the brain. Science 296:678–682

    Article  PubMed  CAS  Google Scholar 

  • Zuardi AW, Shirakawa I, Finkelfarb E, Karniol IG (1982) Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Psychopharmacology 76:245–250

    Article  PubMed  CAS  Google Scholar 

  • Zuurman L, Ippel AE, Moin E, van Gerven JM (2009) Biomarkers for the effects of cannabis and THC in healthy volunteers. Br J Clin Pharmacol 67:5–21

    Article  PubMed  CAS  Google Scholar 

Download references

Disclosure and acknowledgements

The authors have nothing to disclose. This work was funded by the Stanley Medical Research Institute (01-315 and 03-NV-003 to FML), the Koeln Fortune Program (108-2000 and 136-2007 to FML) and the BMBF (01KN0706 to DK).

Author information

Authors and Affiliations

  1. Central Institute of Mental Health, Ruprecht-Karls-University Heidelberg, J5, 68159, Mannheim, Germany

    Dagmar Koethe, Carolin Hoyer & F. Markus Leweke

  2. Department of Psychiatry and Psychotherapy, University of Cologne, 50924, Cologne, Germany

    Dagmar Koethe

Authors
  1. Dagmar Koethe
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Carolin Hoyer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F. Markus Leweke
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to F. Markus Leweke.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Koethe, D., Hoyer, C. & Leweke, F.M. The endocannabinoid system as a target for modelling psychosis. Psychopharmacology 206, 551–561 (2009). https://doi.org/10.1007/s00213-009-1591-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00213-009-1591-7

Keywords

Search

Navigation